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Abstract  
Accurate distant metastasis (DM) prediction is critical for risk stratification and effective 
treatment decisions in breast cancer (BC). Many prognostic markers/models based on tissue 
marker studies are continually emerging using conventional statistical approaches analysing 
complex/dimensional data association with DM/poor prognosis. However, few of them have 
fulfilled satisfactory evidences for clinical application. This study aimed at building DM risk 
assessment algorithm for BC patients.   
 
A well-characterised series of early invasive primary operable BC (n=1902), with 
immunohistochemical (IHC) expression of a panel of biomarkers (n=31) formed the material 
of this study. Decision tree algorithm was computed using WEKA software, utilising 
quantitative biomarkers’ expression and the absence/presence of distant metastases. 
 
Fifteen biomarkers were significantly associated with DM, with six temporal subgroups 
characterised based on time-to-development of DM ranging from < 1 year to > 15 years of 
follow-up. Of these 15 biomarkers, 10 had a significant expression pattern where Ki67LI, 
HER2, p53, N-cadherin, P-cadherin, PIK3CA and TOMM34 showed significantly higher 
expressions with earlier development of DM. In contrast, higher expressions of ER, PR, and 
BCL2, were associated with delayed occurrence of DM. DM prediction algorithm was built 
utilising cases informative for the 15 significant markers. Four risk groups of patients were 
characterised. Three markers; p53, HER2 and BCL2 predicted the probability of DM, based 
on software-generated cut-offs, with a precision rate of 81.1% for positive predictive value 
and 77.3%, for the negative predictive value.  
 
This algorithm reiterates the reported prognostic values of these three markers and 
underscores their central biologic role in BC progression. Further independent validation of 
this pruned panel of biomarkers is therefore warranted.  
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INTRODUCTION 
Distant recurrence is the major cause of cancer related deaths in breast cancer (BC) patients 
[1].  For cancer cells to successfully colonise a secondary site, they have to fulfil specific 
prerequisites to overcome the vast stresses throughout the metastatic cascade [2]. 
Collectively, the success of the metastatic process results from integration and contribution of 
complex molecular pathways controlling cellular proliferation, survival, metabolism, invasion 
and migration [3].  
 
Accuracy in BC prognosis/prediction, particularly distant recurrence risk assessment, is 
critical for accurate patients’ stratification and effective treatment decision making. Many 
prognostic markers and models based on tissue marker studies are continually emerging; 
however, very few of them have fulfilled satisfactory evidence for clinical application. Poor 
study design and misleading statistical analyses have been proposed as to explain 
discrepancies in research studies generating relevant clinically useful prognostic markers [4].   
 
Mining large datasets regarding the expression patterns of a large number of biomarkers and 
clinical variables requires stringent statistical approaches to derive robust conclusions. 
Decision tree is an approach followed to automatically learn, through machine learning, to 
recognise complex patterns and illustrate relations between observed variables to make 
intelligent decisions. Therefore, decision tree algorithms could help improving our basic 
understanding of cancer development and progression [5] which can be used to assist the 
classification of breast cancer cases by sorting them based on feature or attribute values (e.g. 
tissue marker expression). Each node in a decision tree represents a feature in a case to be 
classified, and each branch represents a value that the node can assume. Cases are classified 
starting at the root node and sorted based on their feature values [6]. 
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Perhaps the most common algorithm in literature for building decision trees is the C4.5 
developed by Ross Quinlan. C4.5 is a statistical classifier system which uses the concept of 
information gain to make a tree of classificatory decisions with respect to a previously chosen 
target classification (e.g. distant recurrence). Each attribute of the data can be used to make a 
decision that splits the data into smaller subsets [7]. These outputs are then expressed as 
models, in the form of decision trees or sets of if-then rules, which can be used to classify 
new cases, with an emphasis on making the models understandable as well as accurate. In 
general, it is often possible to prune a decision tree to obtain a simpler and more accurate tree 
[6, 8].   
The aims of this study are to explore biomarkers of greatest impact on distant metastasis 
development in BC patients and their combinatorial behavioural expression patterns, and to 
build a decision tree algorithm for predictive tissue markers of distant metastasis which could 
be used, following validation, in newly diagnosed BC cases.   
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MATERIALS AND METHODS 
Patients and tumours  
This study was based on a well-characterised cohort of early stage (I-III) primary operable 
invasive BC (n=1902) from patients enrolled into the Nottingham Tenovus Primary Breast 
Carcinoma Series between 1987 and 1998, and managed in accordance to a uniform protocol 
and has been comprehensively studied with a broad range of markers [9, 10]. During the 
follow-up time within this series, distant recurrence had developed in 578/1902 cases (30 %). 
The median time to distant metastasis (DM) was 128 months (range 4- 247 months).  
 
This study included 31 biomarkers of clinical and biological relevance to BC tumourigenesis 
and progression [9, 11]. These were: hormone receptors [estrogen receptor (ER), 
progesterone receptor (PR)], epidermal growth factor receptor family members [HER1 
(EGFR), HER2, HER3, HER4], cytokeratins [basal CKs; CK5/6 and CK14, and luminal CKs; 
CK7/8, 18 and 19], tumour suppressor and cell cycle regulator proteins [p53 and P27] anti-
apoptotic BCL2, a proliferation marker (Ki-67/MIB1 clone), cadherin family [E-cadherin, N-
cadherin and P-cadherin], markers of key molecular pathways [TGFβ1, PIK3CA, pAkt-
S473], transcription factors [phospho-STAT3 and TWIST2], markers reported to be 
associated with invasiveness and tumour aggressiveness [CTEN, CD44 and CD24] [12, 13], 
in addition to five markers/proteins encoded by five transcripts/genes significantly expressed 
between metastatic and non-metastatic breast cancer: (TOMM34, ZFN22, KRT23, ST8SIA6, 
and chromogranin-A]. These latter markers resulted from ANN of analysis of cDNA 
expression data of 128 primary invasive frozen BC samples from the Nottingham Tenovus 
Primary Breast Carcinoma series previously studied using gene expression profiling [14]. 
This approach stratified the transcripts on their ability to classify samples based on the 
occurrence of DM (n = 35) compared with those without DM (n = 93), as previously 
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described [15, 16]. These five proteins are encoded by genes/transcripts’ data analysed by 
artificial neuronal network.  These genes were amongst the top 40 differentially expressed 
genes between metastatic and non-metastatic cases. This research was approved by 
Nottingham Research Ethics Committee 2 under the title of ‘‘Development of a molecular 
genetic classification of breast cancer’’. 
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Immunohistochemistry (IHC)  
Four-μm sections were cut from paraffin processed block of previously prepared TMAs and 
mounted on Superfrost slides (Surgipath). MIB1 expression was determined using full face 
FFPE breast tissue sections as previously described [17]. Tissue sections were deparaffinised 
in xylene (Genta Medica, York, UK), rehydrated in descending series of ethanol, 10 seconds 
each. Heat induced retrieval of antigen epitopes was carried out using microwave treatment of 
slides in 10 mM sodium citrate buffer (pH 6.0) for 20 minutes. Slides were then incubated 
primary antibody in optimal working dilution (Table 1). Secondary detection system was 
NovoLink™ Polymer Detection System (Leica, RE7150-K). Reaction was visualised using 
freshly prepared filtered solution of 3-3’ Diaminobenzidine tetrahydrochloride (DAB, Dako, 
K3468). Counterstaining was performed with Mayer’s haematoxylin (DAKO, AR106) for 6 
minutes. Sections were dehydrated in alcohol, cleared in xylene, and coverslipped using DPX 
mounting medium (BDH, Poole, UK).  
 
Assessment of IHC staining   
Slides were scanned as high resolution digital images (0.45µm/pixel) using a NanoZoomer 
slide scanner (Hamamtsu Photonics, Welwyn Garden City, UK) and accessed using a web 
based interface (Distiller, SlidePath Ltd, Dublin, Ireland). TMA cores were scored at 20x 
magnification using a minimum of 24” high resolution screen (1920x1080).  
Scoring of IHC staining of markers was performed using the modified H-score method [18], 
except MIB1LI and BCL2 which were scored as the percentage of expression.  All sections 
were scored without prior knowledge of the patients’ pathologic or outcome data. 
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Statistical analysis  
To establish a set of rules to determine to which group; presence or absence of distant 
metastasis, a patient is more likely to be assigned using its variables’ values; WEKA software 
was used to compute the decision tree algorithm C4.5. Wilcoxon test, a non-parametric 
version of T-test, was used to specify those markers appearing to behave differently in the 
two groups of patients. Results were validated using univariate Cox regression analysis. A p 
value < 0.05 (two-tailed) was considered significant. Box plots were organised to visualise 
the differential distribution of each marker between those cases with metastatic disease from 
those without.   
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RESULTS 
 
Box plots for the distribution of all the 31 markers’ expression within the studied series with 
relevance to the presence or absence of distant metastases is summarised in Figure 1A. 
According these plots, the variable distribution of markers within both patients' subsets can be 
inferred.  For instance, the H-score of PR expression for 95% of cases with DM ranges from 
"0-150", median 5, compared with "0-200", median 90 in cases with no DM.    
 
To test for those markers which were the drivers of the two groups, Wilcoxon test and 
univariate Cox regression analysis were performed. This resulted in a panel consisted of 15 
biomarkers being significantly associated with distant recurrence (p < 0.001).  These markers 
were: Ki67/MIB1LI, ER, PR, HER2, EGFR, p53, BCL2, N-cadherin, P-cadherin, PIK3CA, 
pSTAT3 nuclear expression, TOMM34, ZFN22, CD44 and Ck5/6. Table 2 displays these 
markers and the functional group under which they could be classified. Figure 1B displays 
box plots showing differential expression levels of this panel within metastatic versus non 
metastatic groups of the studied series. As these plots display, variable distribution of 
different markers between the two groups could be appreciated. For instance, the H-score of 
BCL2 expression for 95% of cases with distant recurrence lies between "0-75", median 50, 
compared with "0-100", median 70 in cases with no distant recurrence.  
 
Biomarker Expression Pattern and Time to Distant Metastasis 
Based on time to development of DM in cases where distant recurrence occurred (n=578 
patients), six temporal subgroups were characterised, which ranged from less than one year of 
follow up to more than 15 years. These were: 1) < 1 year (n=50), 2) between 1-2 years 
(n=102), 3) > 2 up to 5 years (n= 201), 4) > 5 up to 10 years (n= 155), 5) > 10 up to 15 years 
(n=56), and 6) > than 15 years (n=14). Box blots were constructed to depict the expression 
pattern of the 15 biomarker panel significantly associated with DM within these temporal 
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subgroups, Figure 2.  According to box plots of these metastatic subgroups, 10 markers had a 
significant expression pattern with respect to time of developing DM. However, the 
remaining five markers did not show this temporal relation with occurrence of DM.  
Markers with Significant Expression Trend within Groups of Time to Distant 
Recurrence  
Within this group of markers, Ki67/MIB1LI, HER2, p53, N-cadherin, P-cadherin, PIK3CA 
and TOMM34 showed characteristic pattern of differential expression between the six 
subgroups, where higher expression values were associated with significantly earlier 
development of distant recurrence, and vice versa. For PIK3CA, the expression values were 
very high for those cases that developed earlier DM (mean H-sore = 210 in those developed 
DM in less than one year compared with 130 in those developed DM > 10 years up to 15 
years). In contrast, higher expression values of ER, PR, and BCL2, were observed to be 
associated with delayed occurrence of DM.     
 Markers with no observed expression trend within the time to distant recurrence 
period:  
The remaining markers, however, (i.e. EGFR, phospho-STAT3, ZFN22, CD44 and CK5/6), 
did not show an evident behavioural/differential trend in their expression with relevance to 
the time to development of distant metastasis in the six metastatic subgroups. 
Decision Tree-Calculated Metastasis Prediction Algorithm  
To build a distant recurrence risk assessment algorithm for breast cancer patients, decision 
trees were computed. For the purpose of robustness, only cases with complete values for all 
biomarkers were used to compute the decision tree. The number of informative cases 
available for the 15 significant markers was 176 cases, which constituted a test set for build a 
decision tree algorithm for metastatic recurrence prediction. DM had developed in 64 (36.3%) 
cases, with the remaining 112 (63.7%) cases remained DM free throughout the period of 
follow-up. The input data for WEKA software was the expression data of these 15 markers, 
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entered as continuous data "H-score or % expression", and the metastatic status (Yes/No), 
with minimum number of cases in each branch to be equal to or more than 4. The resulting 
tree is as illustrated in Figure 3. 
 
According to the tree, four groups of patients were characterised, based on the expression of 
three markers; p53, HER2 and BCL2, which were able to predict the probability of DM in the 
test set. Cut-off points for these three markers were automatically set by the software. Table 3 
displays these groups and the numbers of correctly classified and misclassified cases in each 
of group. 
This ability of this algorithm to classify patients on the basis of probability of DM (i.e. DM 
Yes and DM No) was significantly associated with tumour size, tumour grade, number of 
positive axillary lymph nodes, and BC molecular subtype as assessed by IHC [19]. Although 
associations with axillary nodal stage and lymphovascular invasion (LVI) did not reach 
statistical significance, more proportions of cases with ≥ 4 positive axillary nodes experienced 
DM more than those with node negative disease 30% versus 13.5%, respectively). 
Supplementary Table 1 displays the results of these associations. Multivariate Cox regression 
analysis showed that this algorithm is significantly associated with breast cancer specific 
survival (BCSS) and metastasis free interval [P = 0.001, Hazard ratio (HR) = 3.139, 95% 
interval (CI) = 1.640-6.011, and HR = 2.856, 95% CI = 1.538-5.305, respectively] 
independently of grade, size, stage, molecular subtype and number of positive axillary lymph 
nodes.     
The precision rate of this algorithm in predicting distant metastasis was evaluated using the 
positive predictive value (PPV) and the negative predictive value (NPV) [20]. For this 
algorithm, the PPV = 26/32 = 81.1%, and the NPV= 150/194 = 77.3%.  
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DISCUSSION 
Within the studied series, DM had developed in 30% of cases during the period of follow-up 
and the outcome of this group was markedly reduced compared to patients who did not 
develop DM (5-year survival rate was 58% compared to 98% respectively). This significant 
decline in patients’ survival is, to a large extent, attributable to the biological differences in 
tumours with metastatic potential from those without. Therefore, the molecular factors 
driving growth and differentiation pathways in tumours with metatastes were scrutinised to 
explore their relative contribution in their non-metastatic tumour counterparts.    
 
For this purpose, the expression pattern of 31 biomarkers with close relevance to breast 
cancer biology and progression was studied with relevance to the occurrence of DM. Based 
on their distributions as continuous variables, many of the studied markers displayed variable 
expression within both patients' subsets with and without DM, respectively. However, a panel 
formed of fifteen markers was significantly associated with the occurrence of DM.  
 
Functional categories within this biomarker panel revealed that they belonged to molecular 
pathways responsible for carcinogenesis and cancer progression including: hormonal 
receptors (ER, PR), epidermal growth factor receptor family members (EGFR, HER2), 
tumour growth fraction as assessed by MIBL1, tumour suppressor p53, anti-apoptotic BCL2, 
cell adhesion molecules (N-cadherin, p-cadherin), signalling pathways and transcription 
factors (PIK3CA, pSTAT3, and ZNF22), basal Ck14, TOMM34 and CD44.   
 
In meta-analysis of publicly available breast cancer gene expression profiling (GEP) studies, 
Wirapati and colleagues showed that the key biological drivers in nine prognostic signatures 
were proliferation related genes, in addition to ER signalling and HER2 amplification [21]. 
The current IHC marker panel shared ER, PR, HER2 and proliferative fraction as major 
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drivers of progression with GEP studies [21]. Additionally, p53 and BCL2 were among the 
major contributors of DM in the IHC panel. Inactive TP53, as assessed by positive p53 
protein expression, disturbs the functional braking and emergency cell cycle arrest in 
genetically damaged cells leading ultimately to cell cycle progression [22]. On the other hand, 
BCL2 is a cellular pro-survival molecule that protects transformed cells from apoptotic cell 
death. Therefore, from functional point of view, p53 and BCL2 which were more expressed 
in metastatic cases, lead to enhanced cell proliferation, through cell cycle progression and cell 
immortalisation [23].  
 
The expression of basal/myoepithelial markers has been previously reported to contribute to 
identification of a subset of breast cancer characterised by poor outcome; the basal-like 
subtype [24]. In the current IHC panel, two markers could be assigned into this category of 
markers; EGFR and Ck14. These results support recommendations of using these two 
makers, beside ER, PR and HER2 negativity, as additional surrogates in characterising breast 
cancers with basal phenotype [25]. Moreover, the roles played by PIK3CA in BC progression 
through its downstream effectors, especially through driving an epithelial-to-mesenchymal 
transition program (EMT) with up regulation of N-cadherin and P-cadherin has been reported 
in the same series [26, 27], as well as in others [28].  
 
Metastatic recurrence developed in these patients with primary BC over a time schedule 
ranged from four months to more than 15 years. Ten markers of the IHC biomarker panel 
displayed differential expression patterns within the temporal groups of time to distant 
metastasis. These include: ER, PR, HER2, MIB1LI, p53, BCL2, N-cadherin, P-cadherin, 
PIK3CA and TOMM34. However, the remaining five markers did not show this sort of trend. 
Markers of poor prognostic impact [MIB1LI, HER2, p53, N-cadherin, P-cadherin, PIK3CA 
and TOMM34] were more expressed in cases where DM had manifested earlier; while less 
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expression was observed with prolonged metastasis-free intervals. The reverse was true for 
biomarkers of good prognostic impact [ER, PR, and BCL2]. These findings could be 
interpreted in view of the concept of tumour dormancy, in which disseminated cancer cells 
leaving the primary tumour, stay dormant for variable periods of times in another anatomical 
niche that could extend into many years. During this dormancy stage, cells may remain 
quiescent or form clinically undetectable micrometastases. Entering of these dormant cells or 
micrometastatic nodules into an overt progressive growth phase leads to the commencement 
of clinically detectable metastasis. The length of dormancy periods has been determined by 
balancing cell proliferation and apoptosis [29, 30]. More insight into the differentially 
expressed markers between early and late metastatic groups reveals, once again, that major 
drivers of breast cancer progression, especially proliferation and apoptosis regulator, not only 
play major roles in emergence of recurrences but also in the time of their arousal.  
 
Using the 15 IHC biomarker panel and decision tree, a probabilistic algorithm was computed 
to be applied for risk assessment of DM in breast cancer patients. According to the resulting 
algorithm, four risk groups of patients were characterised. Expression levels of p53, HER2, 
and BCL2 at automatically-generated specific cut-off points were able to predict the 
probability of distant recurrence in the studied set with satisfactory precision rate; 81.1% PPV 
and 77.3% NPV.  Therefore, a tumour suppressor, an oncogene, and an anti-apoptotic marker 
could be reliably used in DM risk prediction. In the root node of the decision tree, p53 
expression was the first determinant, with distant recurrence expected in cases of high p53 
(H-score > 60) with HER2 or p53 high, low HER2 and low BCL2. However, low p53 alone 
or high p53, low HER2 and high BCL2 were associated with lower risk of DM. The ability of 
this probabilistic model in stratifying patients into DM risk groups was significantly 
associated with tumour size, grade, number of positive axillary lymph nodes, and BC 
molecular subtype. Moreover, the model was significantly associated with both BCSS and 
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metastasis free interval, independently of other factors. This algorithm reiterates the 
documented prognostic values of these three markers and underscoring the central biologic 
role played by each of these three markers in breast cancer progression [31-33]. According to 
these results, this small or pruned panel of biomarkers could be used with acceptable success 
in distant recurrence prediction. However, its performance needs to be validated in an 
independent breast cancer patient series especially on a prospective basis.   
 
Conclusions: Metastatic recurrence in the studied series appears to result from contribution of 
a molecular biomarker panel controlling the major nodes in carcinogenic and progression 
pathways including hormonal receptors, growth factors, tumour suppressor, apoptotic 
regulator, cell adhesion apparatus and transcription factors. A predictive algorithm formed of 
p53, BCL2 and HER2 IHC expression was able to successfully predict the probability of 
distant recurrence, which requires independent validation. These findings affirm that 
metastasis is an inherent early cancer trait that could be predicted from the primary tumour 
biomarker expression profile.  
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Figures 
Figure 1: Box plots for the studied markers in cases with no distant recurrence versus those 
with distant recurrence. The box for a certain marker represents 95% of cases. The horizontal 
bold line inside the box is the median value of the marker. A) Distribution of all markers 
(n=31) within the studied series. B: Box plots of biomarker panel showing significant 
expression between metastatic versus non-metastatic patients’ subsets. 
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Figure 2: Box plot showing expression pattern of metastatic biomarker panel within the six 
temporal groups within the metastatic group based on time to DM. A: < 1 year (n=50), B: 
from 1-2 yrs (n=102), C: > 2 up to 5 yrs (n=201), D: > 5 up to 10 yrs (n=155), E: > 10 up to 
15 yrs (n=56), and F: > 15 yrs (n=14). Y axis represents the H-score or percent expression of 
markers on X axis.  
 
 
Figure 3: Decision tree algorithm for predicting distant recurrence. Circles represent the 
markers in the algorithm (p53, HER2, and BCL2). Rectangles represent feature value tested 
(DM); Zero = No DM, One = Yes DM and numbers represent subsets of patients correctly 
classified and misclassified, respectively.  Branches emerging from each marker are levels 
(H-score for p53 and HER2, and percentage of BCL2) of expression below or above which a 
specific case is to be classified into either zero or one. 
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Table1: Dilution and source/clone for the antibodies used in this study.  
 Marker Clone/ Source Dilution 
1 ER  [clone SP1], Dako Corporation 1 : 150 
2 PR [clone PgR 636], Dako Corporation 1:100 
3 HER2 [cerbB-2], Dako Corporation 1:250 
4 EGFR [clone EGFR.113], Novocastra 1:10 
5 EGFR3 [clone RTJ1], Novocastra 1:20 
6 EGFR4   
7 Ki67 [clone MIB-1], Dako Corporation 1 : 50 
8 P53 [DO7], Leica Biosystems, 
Newcastle, UK 
1 : 50 
9 Bcl-2 [clone 124], Dako Corporation 1:400 
10 P27 [Clone SX53G8], Dako 
Corporation 
1:25 
11 PIK3CA Sigma-HPA009985 1:50 
12 pAKT-S474 Neomarkers-RB-10369-P1 1:150 
13 TGFß1 Abcam-Ab27969 1:400 
14 STAT3* Abcam-Ab76315 1:150 
15 TWIST2* Abcam-Ab57997 3g/ml 
16 E-cadherin [clone HECD-1], Zymed 
Laboratories 
1:100 
17 N-cadherin Sigma-C3865 4 g/ml 
18 P-cadherin [clone 56], BD Biosciences 1:200 
19 CTEN* Abcam, ab57940 1:75 
20 CD24** SWA11 mouse antibody 1: 500 
21 CD44 Cell Signalling-156-3c11 1:100 
22 Ck18 [clone DC10], Dako Corporation 1:50 
23 Ck19 [clone BCK 108], Dako 
Corporation 
1:100 
24 Ck7/8 [clone CAM 5.2], Becton 
Dickinson 
1:2 
25 CK5/6 [D5/16134], Boehringer 
Biochemica 
1 : 100 
26 CK14 Anti-human CK14, LL002, 
leicabiosystems,  Newcastle, UK 
1 : 100 
27 Tomm34 Sigma-HPA018845 1: 100 
28 KRT 23 Abnova-H00025984 4g/ml 
29 ST8SIA6 Sigma-HPA011635 1:75 
30 ZFN22 Sigma-HPA016736 1: 100 
31 Chromagranin clone DAK-A3 1:100 
* Microwave heat induced retrieval of antigens’ epitopes was performed in citrate buffer at 
pH 6.0 for all the studied markers except: STAT3, CTEN, and TWIST2 for which EDTA 
solution at pH 8.0 were used.  
**: Gift from Professor P. Altevogt, German Cancer Research Centre, Heidelberg, Germany.  
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Table 2: Functional categories of biomarker panel with the occurrence of distant recurrence 
and their descriptive measures. All markers were scored using H-score (i.e. ranged from 0-
300), except MIB1LI and BCL2 which were scored as percentages (i.e. ranged from 0-100) 
Tissue marker  
Distant Metastasis 
Significance 
p  value 
No Yes 
Hormone receptors       Mean (Median)  
1- ER  115 (125) 93 (100) < 0.001 
2- PR  108 ( 95) 78 (10) < 0.001 
EGFR family members          
3- EGFR  11 (0) 17 (0) 0.002 
4- HER2  30 (0) 52 (0) < 0.001 
Proliferation markers          
5- Ki-67/MIB1LI  28 (14) 39 (30) < 0.001 
Tumour suppressor genes          
6- p53  35 (0) 55 (0) < 0.001 
Anti-apoptotic           
7- BCL2  50 (60) 40 (40) < 0.001 
Key Molecular Pathways            
8- PIK3CA  135 (100) 160 (150) < 0.001 
Cadherin Family members          
9- N-cadherin      120 (100) 130 (100) 0.018 
10- P-cadherin  55 (0) 70 (55) < 0.001 
Transcription Factors          
11-Phospho-STAT3  70 (30) 55 (15) 0.003 
Markers of proposed stem 
cell lineage       
   
12- CD44  80 (50) 60 (10) < 0.001 
Basal CKs           
13- Ck5/6  10 (0) 15 (0) 0.006 
Gene Microarray Genes          
14- Tomm34  90 (90) 115 (100) < 0.001 
15- ZNF22  40 (5) 50 (10) 0.002 
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Table 3: Groups of probability of distant metastasis resulting from decision tree and numbers 
of patients within each group. P53 and HER2 expression were assessed as H-scores, while 
BCL2 was assessed as % of expression.  
Group Correctly classified Misclassified 
Distant metastasis - Yes 
1- p53 > 60 and HER2 > 30 11 1 
2- p53> 60 and HER2 <=30  
     and BCL2 <=10 
15 5 
Distant metastasis - No 
3- p53 <= 60 145 43 
4- p53> 60 and HER2 <= 30 
     and BCL2 > 10 
5 1 
Total 176 50 
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Supplementary Table 1: Statistical associations between DM predication algorithm and BC 
prognostic parameters.   
 
*: The mean number of positive axillary lymph nodes, **: based on t-test.  
 
 
  
 
Variables  
Distant Metastasis  
p-value  (χ2) 
Yes (%) No (%) 
Tumour size (cm) 
        ≤ 2.0 
        > 2.0 
 
88 (92.6) 
62 (76.5) 
 
7 (7.4) 
19 (23.5) 
 
0.003 
(9.988) 
Tumour grade 
        1 
        2 
        3 
 
17 (100) 
56 (98.2) 
77 (75.5) 
 
0 (0) 
1 (1.8) 
25 (24.5) 
 
<0.001 
(18.300) 
Axillary nodal stage 
        1 
        2 
        3 
 
83 (86.5) 
53 (88.3) 
14 (70.0) 
 
13 (13.5) 
7 (11.7) 
6 (30.0) 
 
0.119 
(4.259) 
Number of positive axillary 
lymph nodes  
1.05* 2.54* 
0.015 
    (2.683)** 
Lymphovascular invasion  
     Negative 
     Definite 
 
99 (86.1) 
51 (83.6) 
 
16 (13.9) 
10 (16.4) 
 
0.661 
(0.195) 
Molecular subtype  
Luminal  
HER2 positive 
Triple negative (Basal and non-
Basal) 
 
107 (93.9) 
19 (73.1) 
24 (66.7) 
 
7 (6.1) 
7 (26.9) 
12 (33.3) 
 
<0.001 
(19.649) 
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